title: Targeting the chemokine receptor CCR5: good for HIV, what about other viruses?
authors.forename: Yoav
authors.initials: Y
authors.lastname: Keynan
authors.forename: Jennifer
authors.initials: J
authors.lastname: Juno
authors.forename: Ken
authors.initials: K
authors.lastname: Kasper
authors.forename: Ethan
authors.initials: E
authors.lastname: Rubinstein
authors.forename: Keith R
authors.initials: KR
authors.lastname: Fowke
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D017322:Clinical Trials, Phase II as Topic; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D019713:Receptors, CCR5 / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D010879:Piperazines; D011743:Pyrimidines; D019713:Receptors, CCR5; C486781:vicriviroc